このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a) (JAR2203-SAD-P1)

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of JAR-2203 in Healthy Participants

This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).

調査の概要

状態

募集

条件

介入・治療

詳細な説明

JAR-2203 is an investigational small interfering RNA (siRNA) targeting LPA mRNA to reduce plasma lipoprotein(a) [Lp(a)] levels. This first-in-human, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of JAR-2203 in healthy participants with elevated Lp(a). Approximately 44 participants will be enrolled across six sequential dose cohorts, with dose escalation based on review by a Safety Review Committee.

研究の種類

介入

入学 (推定)

44

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100070
        • 募集
        • Beijing Tiantan Hospital, Capital Medical University

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~60年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Healthy adult male or female participants aged 18-60 years (inclusive) at the time of signing the informed consent form (ICF).
  • At screening, male participants must have a body weight ≥ 50 kg, female participants must have a body weight ≥ 45 kg, and body mass index (BMI) must be 18-28 kg/m² (inclusive).
  • At screening, lipoprotein(a) [Lp(a)] ≥ 30 mg/dL.
  • Male participants and female participants of childbearing potential must agree to use highly effective contraceptive measures throughout the entire study period. Male participants must have no plan to donate sperm; female participants of childbearing potential must have no plan to become pregnant, donate eggs, or undergo oocyte cryopreservation. Female participants must not have had unprotected sexual intercourse within 14 days before screening.
  • Voluntarily sign the ICF and be able to comply with the relevant study requirements and all restrictions during the study period.

Exclusion Criteria:

  • History of clinically significant diseases involving the neuropsychiatric, cardiovascular, respiratory, gastrointestinal, urinary, endocrine/metabolic, immune, musculoskeletal, or hematologic systems, as judged by the investigator.
  • Any clinically significant abnormal findings on physical examination, vital signs, ECG, or laboratory tests, as judged by the investigator.
  • Systolic blood pressure ≥ 140 mmHg or < 90 mmHg, or diastolic blood pressure ≥ 90 mmHg or < 50 mmHg.
  • Fridericia-corrected QT interval (QTcF) > 450 ms.
  • Positive serological results for HBV, HCV antibody (HCV-Ab), HIV antibody (HIV-Ab), or Treponema pallidum antibody (Anti-TP). HBV positivity is defined as either (1) positive HBsAg or (2) positive HBcAb with negative HBsAb.
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN); gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), or total bilirubin (TBiL) > 1.5 × ULN.
  • Estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m².
  • Total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) > 1.2 × ULN; triglycerides (TG) > 2.3 mmol/L.
  • History of clinically significant hypersensitivity, intolerance, or allergic reactions to any drugs, oligonucleotides, foods, or other substances, as judged by the investigator.
  • Acute febrile illness or evidence of active infection within 7 days prior to screening.
  • Administration of any medicinal product within 14 days prior to screening that, in the investigator's judgment, may potentially affect the evaluation outcomes of this study.
  • Receipt of any live vaccine within 1 month before screening, or planned receipt of any live vaccine during the study period.
  • Any surgery within 12 months prior to screening, or planned surgery during the study period.
  • History of alcohol or drug abuse within 1 month prior to screening that, in the investigator's judgment, may potentially affect the evaluation outcomes of this study (alcohol consumption > 14 units/week; 1 unit of alcohol = 350 mL of beer, 150 mL of wine, or 30 mL of spirits).
  • Positive result on breath alcohol test, urine cotinine test, or urine drug screen at screening.
  • Participation as a subject in any pharmaceutical clinical trial within 3 months prior to screening; receipt of any siRNA therapy within 12 months prior to screening; or receipt of any antisense oligonucleotide therapy within 6 months prior to screening.
  • Blood loss or blood donation ≥ 400 mL, or donation of blood products ≥ 2 units, within 3 months prior to screening.
  • Unwilling to abstain from smoking, alcohol consumption, caffeine-containing foods or beverages, strenuous exercise, or other behaviors that may affect drug absorption, distribution, metabolism, and excretion from 24 hours prior to dosing throughout the entire study period.
  • Pregnant or lactating female participants; female participants of childbearing potential with a positive serum HCG test prior to dosing; or participants of reproductive potential who are unable or unwilling to use investigator-approved contraceptive measures throughout the entire study period as instructed by the investigator.
  • History of intolerance to subcutaneous injection, or presence of scars (e.g., surgical or burn scars) at the planned subcutaneous administration site.
  • Poor peripheral venous access.
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:JAR-2203

Participants who receive a single subcutaneous injection of JAR-2203.

JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels are 7.5, 30, 75, 150, 225, and 300 mg.

プラセボコンパレーター:Placebo

Participants who receive a single subcutaneous injection of placebo.

Placebo for injection given as a single subcutaneous injection at a volume matched to the active treatment.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
時間枠:From first dose until the end of the study (through Day 169).

An adverse event is any untoward medical occurrence in a clinical trial participant. A TEAE is any event with onset after administration of the first dose of investigational product and up to and including the end of the study. Clinically significant changes in vital signs, 12-lead electrocardiograms (ECGs), and safety laboratory analytes are included as TEAEs. Severity is graded using NCI-CTCAE v6.0.

From first dose until the end of the study (through Day 169).

二次結果の測定

結果測定
メジャーの説明
時間枠
Maximum Observed Concentration (Cmax) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Time to Reach Maximum Concentration (Tmax) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Terminal Elimination Half-life (t1/2) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC0-24h) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Apparent Total Clearance (CL/F) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Apparent Volume of Distribution (Vz/F) of JAR-2203
時間枠:Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.

Plasma concentrations of JAR-2203 will be measured.

Predose (within 60 minutes before dosing) and at 30 minutes, 1, 2, 4, 6, 8, 12, 24 (Day 2), 36 (Day 2), and 48 (Day 3) hours postdose.
Urinary Excretion Parameters of JAR-2203 (Cohort 5 only)
時間枠:Predose and at 0-6, 6-12,12-24 and 24-48(Day 2) hours postdose

Cumulative amount excreted in urine (Ae), cumulative fraction excreted in urine (Fe), and renal clearance (CLR).

Predose and at 0-6, 6-12,12-24 and 24-48(Day 2) hours postdose
Change From Baseline in Plasma Lipoprotein(a) [Lp(a)] Levels
時間枠:Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Change from baseline in plasma Lp(a) by cohort and scheduled time points.

Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.
Percent Change From Baseline in Plasma Lipoprotein(a) [Lp(a)] Levels
時間枠:Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Percent change from baseline in plasma Lp(a) by cohort and scheduled time points.

Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.
Change From Baseline in Other Lipid and Lipoprotein Parameters
時間枠:Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

Change from baseline in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and triglycerides (TG).

Predose (within 60 minutes before dosing), at 12, 24 (Day 2), and 48 (Day 3) hours postdose, and at Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169.

その他の成果指標

結果測定
メジャーの説明
時間枠
Immunogenicity
時間枠:Predose (within 60 minutes before dosing) and at Days 15, 29, and 57.

Incidence of anti-drug antibodies (ADA) and, if applicable, neutralizing antibodies (NAb).

Predose (within 60 minutes before dosing) and at Days 15, 29, and 57.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月19日

一次修了 (推定)

2027年7月30日

研究の完了 (推定)

2027年11月30日

試験登録日

最初に提出

2026年11月8日

QC基準を満たした最初の提出物

2026年11月8日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月8日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • JAR-2203-1001
  • ChiCTR2600134394 (その他の識別子:Chinese Clinical Trial Registry)
  • 2026LP02024 (その他の識別子:National Medical Products Administration, China)
  • CTR20263460 (その他の識別子:Center for Drug Evaluation, NMPA, China)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) from this study will not be shared. This is an early-phase study in a small number of healthy participants, and the sponsor does not expect the limited participant-level data to provide meaningful additional scientific value beyond the aggregated results that will be reported. The data also contain proprietary information regarding an investigational product.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。